Download Sample
Add to CartBile Duct Cancer (Cholangiocarcinoma) Market
By Treatment Type;
Chemotherapy -[Gemcitabine-Based, Cisplatin-Based, Combination Therapies and Others], Targeted Therapy -[Epidermal Growth Factor Receptor (EGFR) Inhibitors, Vascular Endothelial Growth Factor (VEGF) Inhibitors and Others], Radiation Therapy, Immunotherapy, Surgery and OthersBy Disease Type;
Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma (Klatskin Tumors) and Distal CholangiocarcinomaBy Distribution Channel;
Hospital Pharmacies, Retail Pharmacies and Online PharmaciesBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Bile Duct Cancer (Cholangiocarcinoma) Market Overview
Bile Duct Cancer (Cholangiocarcinoma) Market (USD Million)
Bile Duct Cancer (Cholangiocarcinoma) Market was valued at USD 404.47 million in the year 2024. The size of this market is expected to increase to USD 693.19 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.0%.
Bile Duct Cancer (Cholangiocarcinoma) Market
*Market size in USD million
CAGR 8.0 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 8.0 % |
| Market Size (2024) | USD 404.47 Million |
| Market Size (2031) | USD 693.19 Million |
| Market Concentration | Medium |
| Report Pages | 344 |
Major Players
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Novartis International AG
- Bayer AG
- AstraZeneca PLC
- Eli Lilly and Company
- AbbVie Inc.
- Celgene Corporation
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Bile Duct Cancer (Cholangiocarcinoma) Market
Fragmented - Highly competitive market without dominant players
The Bile Duct Cancer (Cholangiocarcinoma) Market is gaining prominence with rising awareness and advancements in oncology research. Improved early detection rates have increased by nearly 20% due to biomarker-based screening and advanced imaging tools. This shift is enabling more accurate diagnosis and effective treatment options, driving significant adoption of innovative therapies.
Growing Focus on Targeted Therapies
The demand for targeted treatments is expanding, with over 35% of protocols incorporating precision medicine. These therapies directly address genetic mutations in tumor cells, improving patient outcomes while reducing harmful side effects. The emphasis on personalized medicine is redefining the approach to cholangiocarcinoma treatment.
Advancements in Immunotherapy
Adoption of immunotherapy has surged by approximately 30%, as more patients benefit from therapies that empower the immune system to fight tumor growth. Clinical trials have shown encouraging results, boosting confidence in these treatments. With expanding research, immunotherapy is positioned to play a stronger role in treatment pathways for bile duct cancer.
Investment in Research and Development
Nearly 40% of ongoing oncology projects now focus on rare cancers, including cholangiocarcinoma. Pharmaceutical and biotech companies are increasing funding toward next-generation drug discoveries. These R&D efforts are paving the way for breakthrough therapies that enhance survival and quality of life for patients.
Bile Duct Cancer (Cholangiocarcinoma) Market Recent Developments
-
New Drug Approvals: Recent FDA approvals of targeted therapies for bile duct cancer, such as pemigatinib and ivosidenib, offer new treatment options for patients with specific genetic mutations, enhancing treatment efficacy and patient survival rates.
-
Innovative Diagnostic Tools: Development of advanced diagnostic tools, including liquid biopsy and next-generation sequencing, is improving early detection and personalized treatment approaches, leading to better patient outcomes and expanding the market.
Segment Analysis
The Global Bile Duct Cancer (Cholangiocarcinoma) Market report delves into various segments of the market to provide a comprehensive analysis. It includes an in-depth assessment of each segment, including drug therapy, radiation therapy, and surgery, offering insights into the historic and forecasted revenue trends. The analysis is backed by relevant data points, such as market size, growth rates, and key trends, allowing stakeholders to understand the dynamics shaping the market landscape. By examining historical data and projecting future trends, the report provides a clear picture of the market's evolution over time, aiding in strategic decision-making.
For drug therapy, the report analyzes the market's performance based on factors like drug classes, treatment regimens, and adoption rates. It delves into the efficacy and safety profiles of existing drugs, as well as the emergence of novel therapies such as targeted drugs and immunotherapies. The revenue analysis for drug therapy considers market shares of key players, pricing trends, and reimbursement policies, providing a comprehensive outlook for this segment. Insights derived from data trends and patterns help identify growth opportunities and potential challenges in the drug therapy segment.
The report scrutinizes the radiation therapy and surgery segments, examining technological advancements, treatment protocols, and outcomes. It assesses the market shares of radiation therapy equipment manufacturers and surgical device providers, highlighting competitive dynamics and market trends. By leveraging historical data and forecasting future developments, the report equips stakeholders with actionable insights to capitalize on market opportunities and mitigate risks. Overall, the report offers a detailed and data-driven analysis of the Global Bile Duct Cancer (Cholangiocarcinoma) Market, enabling informed decision-making and strategic planning for market participants.
The Global Bile Duct Cancer (Cholangiocarcinoma) Market is segmented by Treatment Provider into Hospitals, Oncology Centers & Specialty Clinics, and Ambulatory Surgical Centers (ASCs). Hospitals are the primary treatment providers, offering comprehensive care with advanced diagnostics, surgeries, and therapies for complex cases. Oncology Centers & Specialty Clinics focus on cancer-specific treatments and personalized care, providing expertise in managing cholangiocarcinoma. Ambulatory Surgical Centers (ASCs) cater to outpatient treatments, offering cost-effective, less invasive procedures for certain cases, and follow-up care. Each segment plays a crucial role in delivering tailored care for bile duct cancer patients.
Global Bile Duct Cancer (Cholangiocarcinoma) Segment Analysis
In this report, the Global Bile Duct Cancer (Cholangiocarcinoma) Market has been segmented by Product Type, Treatment, Treatment Provider and Geography.
Global Bile Duct Cancer (Cholangiocarcinoma) Market, Segmentation by Product Type
In this report, the Global Bile Duct Cancer (Cholangiocarcinoma) Market has been segmented by Product Type into Drug Therapy, Radiation Therapy and Surgery.
The Global Bile Duct Cancer (Cholangiocarcinoma) Market is segmented by product type into three primary categories: drug therapy, radiation therapy, and surgery. Drug therapy encompasses the use of chemotherapeutic agents, targeted therapies, and immunotherapies to treat bile duct cancer. Chemotherapy remains a cornerstone in managing cholangiocarcinoma, often utilized to shrink tumors pre-surgery or to manage advanced-stage disease. Recently, targeted therapies and immunotherapies have gained traction, offering more personalized treatment options by targeting specific genetic mutations and immune pathways involved in cancer progression. These novel therapies have shown promising results in clinical trials, contributing to a gradual shift in treatment paradigms.
Radiation therapy involves using high-energy radiation to destroy cancer cells or inhibit their growth. This modality is often employed as an adjunct to surgery or when surgical options are not viable. Advances in radiation technology, such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), have enhanced the precision and efficacy of radiation treatments, reducing damage to surrounding healthy tissues. Radiation therapy plays a crucial role in palliative care by alleviating symptoms and improving the quality of life for patients with unresectable bile duct cancer. The integration of radiotherapy with other treatment modalities is being explored to maximize therapeutic outcomes.
Surgery remains the most definitive treatment for cholangiocarcinoma, particularly for early-stage and localized tumors. Surgical interventions include bile duct resection, partial hepatectomy, and liver transplantation, depending on the tumor’s location and extent. Successful surgical outcomes heavily rely on early detection and precise tumor staging. Despite being the most curative option, surgery is feasible for a limited number of patients due to the typically late presentation of the disease. Advances in surgical techniques and perioperative care have improved the safety and effectiveness of these procedures, though the need for better early diagnostic methods remains critical.
The Global Bile Duct Cancer (Cholangiocarcinoma) Market is witnessing significant developments across these three product types. Each modality—drug therapy, radiation therapy, and surgery—plays a vital role in the comprehensive management of bile duct cancer. Continued research and clinical advancements are expected to enhance treatment outcomes and expand therapeutic options, ultimately driving market growth.
Global Bile Duct Cancer (Cholangiocarcinoma) Market, Segmentation by Treatment
In this report, the Global Bile Duct Cancer (Cholangiocarcinoma) Market has been segmented by Treatment into Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer.
The Global Bile Duct Cancer (Cholangiocarcinoma) Market is segmented by application into two main categories: intrahepatic bile duct cancer and extrahepatic bile duct cancer. Intrahepatic bile duct cancer originates within the liver and is typically more challenging to detect early due to its location and the lack of specific symptoms in the initial stages. This type of cholangiocarcinoma has seen a rise in incidence over the past few years, driven by factors such as chronic liver diseases, hepatitis infections, and increasing exposure to carcinogenic substances. Advanced diagnostic technologies, such as imaging techniques and genetic profiling, have improved early detection rates, thereby enhancing treatment outcomes.
Extrahepatic bile duct cancer, on the other hand, occurs outside the liver, within the bile ducts that lead to the small intestine. This type is more common than intrahepatic bile duct cancer and can be further divided into perihilar (occurring at the hilum where the left and right bile ducts meet) and distal (occurring further down the bile duct near the intestine). Extrahepatic bile duct cancer often presents earlier with symptoms such as jaundice, leading to relatively quicker diagnosis compared to intrahepatic cases. Treatment approaches for extrahepatic bile duct cancer typically include surgery, radiation therapy, and chemotherapy, with emerging targeted therapies and immunotherapies showing promise in clinical trials.
Both segments of bile duct cancer face significant challenges, including late-stage diagnosis and limited treatment options. However, ongoing research and development are paving the way for more effective therapies tailored to the specific types and stages of cholangiocarcinoma. The market for both intrahepatic and extrahepatic bile duct cancer is driven by advancements in personalized medicine, increasing awareness, and better diagnostic tools. As a result, the Global Bile Duct Cancer (Cholangiocarcinoma) Market is expected to grow, with improved patient outcomes and expanded therapeutic options contributing to this positive trend.
Global Bile Duct Cancer (Cholangiocarcinoma) Market, Segmentation by Treatment Provider
In this report, the Global Bile Duct Cancer (Cholangiocarcinoma) Market has been segmented by Treatment Provider into Hospitals, Oncology Centers & Specialty Clinics, and Ambulatory Surgical Centers (ASCs).
Hospitals are the largest segment, as they provide comprehensive care for bile duct cancer patients, including advanced diagnostic services, surgical interventions, chemotherapy, and radiation therapy. Hospitals are equipped with specialized medical teams and cutting-edge technology to manage complex cases, which makes them the preferred choice for patients requiring intensive and multidisciplinary care. Oncology Centers & Specialty Clinics are also significant treatment providers, focusing specifically on cancer care. These centers offer specialized expertise in the diagnosis and treatment of cholangiocarcinoma, often providing personalized care plans, clinical trials, and advanced treatment options like targeted therapy or immunotherapy. Their focus on oncology allows for a high level of specialization, making them a popular option for patients seeking cancer-specific care.
Ambulatory Surgical Centers (ASCs) are smaller, outpatient facilities where patients undergo surgeries or treatments that do not require an overnight stay. ASCs are gaining popularity for certain bile duct cancer treatments, particularly for less invasive procedures or follow-up care. These centers are more cost-effective compared to hospitals and offer a streamlined experience, making them an attractive option for patients requiring certain procedures or those with milder forms of the disease. Each treatment provider segment plays a crucial role in the overall management of bile duct cancer, with hospitals leading in complex and comprehensive care, while oncology centers, specialty clinics, and ASCs provide more focused, cost-effective, and specialized treatment options.
Global Bile Duct Cancer (Cholangiocarcinoma) Market, Segmentation by Geography
In this report, the Global Bile Duct Cancer (Cholangiocarcinoma) Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Bile Duct Cancer (Cholangiocarcinoma) Market Share (%), by Geographical Region, 2024
The Global Bile Duct Cancer (Cholangiocarcinoma) Market is characterized by varying regional market shares, driven by differences in healthcare infrastructure, prevalence rates, and access to advanced treatment options. North America holds a significant share of the market, attributed to the region's robust healthcare system, high awareness levels, and extensive research and development activities. The United States, in particular, benefits from the presence of leading pharmaceutical companies and research institutions that are actively involved in developing novel therapies and diagnostics for bile duct cancer. Additionally, favorable reimbursement policies and strong healthcare expenditure further bolster the market in this region.
In Europe, the market is also substantial, with countries like Germany, France, and the United Kingdom leading in terms of market share. The European market is driven by advanced healthcare infrastructure, high prevalence of bile duct cancer, and a strong focus on research and clinical trials. European healthcare systems are known for their comprehensive cancer treatment programs, which include access to cutting-edge therapies and supportive care. The region's commitment to healthcare innovation and the presence of numerous research consortia contribute to the growth and development of the bile duct cancer market.
Asia-Pacific represents a rapidly growing market for bile duct cancer treatment, driven by increasing incidence rates and improving healthcare infrastructure. Countries such as China, Japan, and India are experiencing significant market growth due to rising healthcare investments, expanding access to advanced medical technologies, and increasing public awareness about cancer. The region's large and aging population contributes to a higher incidence of bile duct cancer, necessitating effective treatment solutions. Additionally, the growing focus on medical tourism in countries like India and Thailand offers affordable and high-quality cancer treatment options, further propelling market growth in the Asia-Pacific region.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Bile Duct Cancer (Cholangiocarcinoma) Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing incidence rates
- Advanced diagnostic technologies
- Growing healthcare expenditure
- Rising awareness campaigns
-
Enhanced treatment options : Enhanced treatment options are significantly driving the Global Bile Duct Cancer (Cholangiocarcinoma) Market. Recent advancements in medical technology and pharmaceutical research have led to the development of more effective treatments. This includes targeted therapies and immunotherapies that offer higher efficacy and fewer side effects compared to traditional chemotherapy. Targeted therapies, for instance, focus on specific genetic mutations within cancer cells, thereby improving treatment outcomes and patient survival rates.
The advent of immunotherapy has revolutionized cancer treatment by leveraging the body's immune system to fight cancer cells. Drugs like immune checkpoint inhibitors have shown promise in treating bile duct cancer by blocking proteins that prevent immune cells from attacking cancer. Clinical trials and research studies are continuously exploring new drug combinations and therapies, leading to an expanding arsenal of treatment options for patients. These innovations not only improve the quality of life for patients but also enhance the overall prognosis.
Advancements in minimally invasive surgical techniques and radiation therapy have contributed to better treatment outcomes. Techniques such as laparoscopic surgery and stereotactic body radiotherapy (SBRT) provide precise and less invasive options for tumor removal and management. These methods reduce recovery times and minimize complications, making treatment more accessible and effective for patients. The integration of these advanced treatment modalities into standard care practices is expected to drive significant growth in the bile duct cancer market, offering hope for improved patient outcomes and long-term survival.
Restraints
- High treatment costs
- Limited early detection
- Insufficient research funding
- Complex regulatory approvals
-
Low awareness levels : Low awareness levels about bile duct cancer, also known as cholangiocarcinoma, significantly restrain the market's growth. Many people, including healthcare professionals, lack sufficient knowledge about the symptoms and risk factors associated with this rare type of cancer. This results in delayed diagnoses and treatment, which are critical factors in patient prognosis. Early detection is crucial for effective treatment, but the lack of awareness often means that the disease is diagnosed at an advanced stage when treatment options are limited and less effective.
Public awareness campaigns are relatively sparse, and the medical community does not always prioritize bile duct cancer compared to more common cancers like breast or lung cancer. This discrepancy in focus leads to lower funding for research and fewer resources dedicated to improving diagnostic and treatment methods for cholangiocarcinoma. The absence of high-profile advocacy and education initiatives means that patients and their families are often uninformed about the disease, its symptoms, and the importance of early screening.
Addressing low awareness levels requires a multi-faceted approach involving increased funding for research, better education for healthcare providers, and widespread public awareness campaigns. Medical institutions and cancer organizations need to collaborate on disseminating information about bile duct cancer to the general public and healthcare professionals. This can be achieved through educational programs, media campaigns, and support groups that highlight the importance of early detection and available treatment options. Improving awareness not only aids in early diagnosis and better treatment outcomes but also encourages funding and research efforts to develop new therapies, ultimately benefiting the entire healthcare system.
Opportunities
- Emerging market potential
- Innovative drug developments
- Improved healthcare infrastructure
- Collaborations and partnerships
-
Personalized medicine advancements : Personalized medicine advancements present significant opportunities in the Global Bile Duct Cancer (Cholangiocarcinoma) Market. Personalized medicine, also known as precision medicine, involves tailoring treatment to individual patient characteristics, such as genetic makeup, lifestyle, and environment. This approach is particularly promising for bile duct cancer, where genetic mutations and variations play a crucial role in the disease's progression and response to treatment. By leveraging genetic profiling and biomarker analysis, healthcare providers can develop more effective, targeted treatment plans that improve patient outcomes.
One of the primary benefits of personalized medicine is its potential to identify specific genetic mutations that drive cancer growth. For example, mutations in the FGFR2 gene have been identified in a subset of cholangiocarcinoma patients, leading to the development of targeted therapies that specifically inhibit these mutations. Such treatments have shown considerable promise in clinical trials, offering new hope for patients who may not respond well to conventional therapies. Personalized medicine also allows for the identification of potential resistance mechanisms, enabling adjustments in treatment strategies to overcome these challenges.
Advancements in personalized medicine contribute to the development of companion diagnostics, which are tests designed to determine the most effective treatment for individual patients. These diagnostics can identify patients who are most likely to benefit from specific therapies, thereby optimizing treatment efficacy and minimizing unnecessary side effects. As research in this field progresses, we can expect to see more sophisticated diagnostic tools and targeted therapies that cater to the unique genetic and molecular profiles of bile duct cancer patients. This evolution in treatment strategy not only enhances patient care but also drives market growth by introducing innovative, high-value products and services.
Bile Duct Cancer (Cholangiocarcinoma) Market Competitive Landscape Analysis
Bile Duct Cancer (Cholangiocarcinoma) Market is experiencing rising competition as pharmaceutical companies adopt strategies centered on innovation, partnerships, and precision oncology. Over 45% of the market share is held by top firms, with merger activities and collaboration driving efficiency. Companies are investing in targeted therapies and immunotherapies to support growth across global oncology care segments.
Market Structure and Concentration
The market shows moderate concentration, with more than 55% share dominated by established biopharmaceutical players pursuing expansion. Smaller firms focus on niche oncology research, while leading companies leverage collaboration with cancer institutes and clinical networks. Ongoing technological advancements in biomarkers and companion diagnostics continue to support growth, reshaping treatment approaches for cholangiocarcinoma.
Brand and Channel Strategies
Over 60% of revenue is tied to strong brand recognition and specialized channel strategies targeting hospitals, oncology clinics, and research organizations. Leading enterprises strengthen partnerships with healthcare providers to ensure timely access. Adaptive strategies in digital platforms, clinical collaborations, and patient-support programs continue to reinforce growth, driving wider adoption of bile duct cancer therapies.
Innovation Drivers and Technological Advancements
More than 65% of firms focus on R&D innovation in targeted molecules, immuno-oncology, and gene-based therapies. Technological advancements in drug delivery, biomarker discovery, and trial designs form the backbone of competitive strategies. Strong collaboration between pharma firms, research labs, and oncology centers drives growth, enabling improved patient outcomes in rare cancer treatment landscapes.
Regional Momentum and Expansion
Regional leaders account for nearly 50% of market expansion through tailored strategies and healthcare partnerships. North America leads due to strong oncology infrastructure, while Europe emphasizes biosimilars and precision medicine. Asia-Pacific demonstrates rapid growth with increasing cancer prevalence and clinical research activity. Firms continue investing in innovation hubs and manufacturing capabilities to strengthen competitiveness.
Future Outlook
The future outlook suggests more than 70% of enterprises will prioritize expansion, next-generation technological advancements, and collaborative strategies. Sustained innovation in immunotherapies, targeted drugs, and mergers will reshape the competitive environment. Companies are expected to reinforce growth by aligning with precision oncology trends and improving global access to cholangiocarcinoma treatments.
Key players in Bile Duct Cancer (Cholangiocarcinoma) Market include :
- Pfizer Inc.
- GlaxoSmithKline plc
- AbbVie Inc.
- Novartis AG
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Johnson & Johnson
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Delcath Systems Inc.
- Kyowa Hakko Kirin Co., Ltd.
- Bayer AG
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- market share analysis.
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Bile Duct Cancer (Cholangiocarcinoma) Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing incidence rates
- Advanced diagnostic technologies
- Growing healthcare expenditure
- Rising awareness campaigns
- Enhanced treatment options
- Restraints
- High treatment costs
- Limited early detection
- Insufficient research funding
- Complex regulatory approvals
- Low awareness levels
- Opportunities
- Emerging market potential
- Innovative drug developments
- Improved healthcare infrastructure
- Collaborations and partnerships
- Personalized medicine advancements
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers
- Drivers, Restraints and Opportunities
- Market Segmentation
- Bile Duct Cancer (Cholangiocarcinoma) Market, By Treatment Type, 2021 - 2031 (USD Million)
- Chemotherapy
- Gemcitabine-Based
- Cisplatin-Based
- Combination Therapies
- Others
- Targeted Therapy
- Epidermal Growth Factor Receptor (EGFR) Inhibitors
- Vascular Endothelial Growth Factor (VEGF) Inhibitors
- Others
- Radiation Therapy
- Immunotherapy
- Surgery
- Others
- Chemotherapy
- Bile Duct Cancer (Cholangiocarcinoma) Market, By Disease Type, 2021 - 2031 (USD Million)
- Intrahepatic Cholangiocarcinoma
- Extrahepatic Cholangiocarcinoma
- Perihilar Cholangiocarcinoma (Klatskin Tumors)
- Distal Cholangiocarcinoma
- Bile Duct Cancer (Cholangiocarcinoma) Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Bile Duct Cancer (Cholangiocarcinoma) Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Bile Duct Cancer (Cholangiocarcinoma) Market, By Treatment Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Pfizer Inc.
- GlaxoSmithKline plc
- AbbVie Inc.
- Novartis AG
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Johnson & Johnson
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Delcath Systems Inc.
- Kyowa Hakko Kirin Co., Ltd.
- Bayer AG
- Company Profiles
- Analyst Views
- Future Outlook of the Market